SUGAR LAND, TX (July 20, 2018) – Healix, the nation’s leader in physician office based infusion services, announced a strategic relationship with DoseMe, a precision dosing decision support platform specifically for clinical practice. “We are really pleased to partner...
BOSTON and SUGAR LAND, Texas, December 18, 2017 – TA Associates, a leading global growth private equity firm, today announced that it has completed a strategic growth investment in Healix, a provider of outsourced alternate-site infusion therapy management services....
SUGAR LAND, TX (July 28, 2017) – Healix Infusion Therapy, Inc. is proud to announce the relocation of its pharmacy operation to a new, state-of-the-art facility in Sugar Land, Texas. With more than 28 years of sterile compounding services, the Healix Infusion Therapy...
SUGAR LAND, TX (July 28, 2017) – Healix® is Now a National Provider of Trogarzo™ (ibalizumab-uiyk). Trogarzo™ is a new humanized monoclonal antibody for the treatment of multidrug-resistant (MDR) HIV-1 infection. This drug has a new mechanism of action and is the...
SUGAR LAND, TX (July 14, 2017) – Gram-positive osteomyelitis was successfully treated with telavancin, as published in an article in The International Journal of Antimicrobial Agents. Primary author was Claudia P. Schroeder, Clinical Research Lead at Healix®, in...
SUGAR LAND, TX (March 20, 2017) – Healix has been selected among an exclusive number of distributers to become a national provider of Cuvitru [Immune Globulin Subcutaneous (Human)] 20%. Immunologists who partner with Healix receive a collection of clinical and...
![Healix® is Now a National Provider of Cuvitru® [Immune Globulin Subcutaneous (Human)] 20%](https://healix.net/wp-content/uploads/pic-cuvitru.jpg)
Recent Comments